{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:50:09Z","timestamp":1787071809351,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of 2 mg intravitreal triamcinolone acetonide (IVTA) in the management of serpiginous-like choroiditis (SLC), and study lesion resolution, recurrence, paradoxical worsening, and systemic medication burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective observational study included patients with SLC receiving 2 mg IVTA with a minimum follow-up of 6 months. Demographic data, clinical findings, imaging, and treatment details were retrieved from medical records. The primary outcomes were time to lesion resolution, incidence of paradoxical worsening, recurrence rate, and the need for repeat IVTA. Secondary outcomes were changes in best-corrected visual acuity (BCVA) and intraocular pressure (IOP). Use of systemic corticosteroids was also recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Fifteen eyes of 14 patients were analyzed. The mean age was 31.5 years, and 71.4% were managed without systemic corticosteroids. All patients received IVTA; 11 received concurrent anti-tubercular therapy (ATT). Mantoux positivity was observed in 64.2%, QuantiFERON-TB Gold in 78.5%, and both were positive in 57.1% of patients. Mean clinical and fundus autofluorescence (FAF)-based lesion resolution time was 2.7 and 5.9 months, respectively. No cases of paradoxical worsening were noted. Recurrence occurred in three eyes, two of which did not receive ATT. Mean BCVA improved from 20\/50 to 20\/32 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006). IOP elevation &gt;21 mm Hg occurred in 33.3% of eyes and was controlled with topical medications. Cataract developed in 38.4% of eyes, and one eye required surgery. The mean follow-up was 18.2 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IVTA at a 2 mg dose appears effective in lesion resolution, while minimizing systemic therapy in SLC, with an acceptable safety profile and no paradoxical worsening. Larger prospective studies are needed to validate these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1675_25","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T17:00:10Z","timestamp":1765558810000},"page":"548-553","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Intravitreal triamcinolone acetonide therapy in serpiginous-like choroiditis"],"prefix":"10.4103","volume":"74","author":[{"given":"Ankush","family":"Kawali","sequence":"first","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Anupama","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Bhakti","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmamalini","family":"Mahendradas","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"R1-20260416","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/S0161-6420(03)00619-5","article-title":"Presumed tubercular serpiginous-like choroiditis","volume":"110","author":"Gupta","year":"2003","journal-title":"Ophthalmology"},{"key":"R2-20260416","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archophthalmol.2010.116","article-title":"Clinical features of tuberculous serpiginous-like choroiditis in contrast to classic serpiginous choroiditis","volume":"128","author":"Vasconcelos-Santos","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R3-20260416","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.ophtha.2012.05.034","article-title":"Tubercular serpiginous-like choroiditis presenting as multifocal serpiginoid choroiditis","volume":"119","author":"Bansal","year":"2012","journal-title":"Ophthalmology"},{"key":"R4-20260416","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0301-4738.15295","article-title":"Intravitreal triamcinolone acetonide in serpiginous choroidopathy","volume":"53","author":"Pathengay","year":"2005","journal-title":"Indian J Ophthalmol"},{"key":"R5-20260416","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/ICB.0000000000000767","article-title":"Treatment of refractory tubercular serpiginous-like choroiditis with intravitreal methotrexate","volume":"15","author":"Tsui","year":"2021","journal-title":"Retin Cases Brief Rep"},{"key":"R6-20260416","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/IAE.0000000000003481","article-title":"Idiopathic multifocal choroiditis with serpiginous-like peripapillary chorioretinal atrophy","volume":"42","author":"Moussa","year":"2022","journal-title":"Retina"},{"key":"R7-20260416","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09273948.2021.2002367","article-title":"Adjunctive intravitreal anti-vascular endothelial growth factor and moxifloxacin therapy in management of intraocular tubercular granulomas","volume":"31","author":"Agarwal","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"R8-20260416","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/09273948.2017.1383446","article-title":"Clinical outcomes of adjunctive sustained- release intravitreal dexamethasone implants in tuberculosis-associated multifocal serpigenoid choroiditis","volume":"26","author":"Jain","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R9-20260416","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/09273940600826604","article-title":"Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis","volume":"14","author":"Ozkiris","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"R10-20260416","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2018.07.003","article-title":"Treatment duration and side effect profile of long-term use of intravitreal preservative-free triamcinolone acetonide in uveitis","volume":"194","author":"Ganapathy","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R11-20260416","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1080\/09273948.2017.1400074","article-title":"The role of dexamethasone implant in the management of tubercular uveitis","volume":"26","author":"Agarwal","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R12-20260416","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000252981","article-title":"Prospective evaluation of intravitreal triamcinolone acetonide in serpiginous choroiditis","volume":"224","author":"Wadhwa","year":"2010","journal-title":"Ophthalmologica"},{"key":"R13-20260416","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/09273948.2017.1373829","article-title":"Ultra-wide field imaging in paradoxical worsening of tubercular multifocal serpiginoid choroiditis after the initiation of anti-tubercular therapy","volume":"27","author":"Aggarwal","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R14-20260416","first-page":"1","article-title":"Serpiginous-like choroiditis (SLC) - morphology and treatment outcomes","volume":"12","author":"Kawali","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"R15-20260416","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4103\/ijo.IJO_1518_19","article-title":"Peripheral serpiginous like choroiditis: A unique and unheard entity","volume":"68","author":"Mishra","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R16-20260416","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.4103\/ijo.IJO_1451_20","article-title":"Ocular tuberculosis: Where are we today?","volume":"68","author":"Testi","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"R17-20260416","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3928\/23258160-20210727-05","article-title":"Choroidal thickness in multifocal dendritic and placoid serpiginous-like choroiditis: A comparative study","volume":"52","author":"Kawali","year":"2021","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R18-20260416","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1001\/jamaophthalmol.2017.5791","article-title":"Clinicopathologic features of tuberculous serpiginous-like choroiditis","volume":"136","author":"Kawali","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R19-20260416","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12879-024-10288-1","article-title":"A systemic review of the utility of antituberculosis therapy for presumed tuberculous uveitis","volume":"25","author":"Taylor","year":"2025","journal-title":"BMC Infect Dis"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1675_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:56:33Z","timestamp":1787068593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_1675_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1675_25","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-07-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}